Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 4
2016 pubmed

Antimicrobial Peptide P60.4Ac-Containing Creams and Gel for Eradication of Methicillin-Resistant Staphylococcus aureus from Cultured Skin and Airway Epithelial Surfaces.

Haisma. Elisabeth M EM; Göblyös. Anikó A; Ravensbergen. Bep B; Adriaans. Alwin E AE; Cordfunke. Robert A RA; Schrumpf. Jasmijn J; Limpens. Ronald W A L RW; Schimmel. Kirsten J M KJ; den Hartigh. Jan J; Hiemstra. Pieter S PS; Drijfhout. Jan Wouter JW; El Ghalbzouri. Abdoelwaheb A; Nibbering. Peter H PH

Key Findings

  • 0.1% P60.4Ac in hypromellose gel kills >99% planktonic MRSA and >85% biofilm MRSA on skin models
  • The gel formulation remains stable for at least 3 months, unlike the Cetomacrogol cream
  • No cytotoxic effects observed up to 2% P60.4Ac on skin cells and up to 0.5% on airway epithelial cells

Practical Outcomes

  • For DIY skin or nasal decolonization, mix P60.4Ac into a hypromellose (hydroxypropyl methylcellulose) gel at 0.1–0.5% concentration. Apply the gel to affected areas; it should rapidly reduce MRSA without damaging host cells and can be stored for several months.

Summary

A peptide called P60.4Ac works best when mixed into a simple gel (hypromellose) rather than creams. In lab skin and airway models it wipes out most MRSA bacteria, even the tougher biofilm form, at low concentrations and doesn’t hurt the cells. The gel stays stable for months, making it a practical way to apply the peptide on skin or mucosal surfaces.

Abstract

We previously found the LL-37-derived peptide P60.4Ac to be effective against methicillin-resistant Staphylococcus aureus (MRSA) on human epidermal models (EMs). The goal of this study was to identify the preferred carrier for this peptide for topical application on skin and mucosal surfaces. We prepared P60.4Ac in three formulations, i.e., a water-in-oil cream with lanolin (Softisan 649), an oil-in-water cream with polyethylene glycol hexadecyl ether (Cetomacrogol), and a hydroxypropyl methylcellulose (hypromellose) 4000 gel. We tested the antimicrobial efficacy of the peptide in these formulations against mupirocin-resistant and -sensitive MRSA strains on EMs and bronchial epithelial models (BEMs). The cytotoxic effects of formulated P60.4Ac on these models were determined using histology and WST-1 and lactate dehydrogenase assays. Moreover, we assessed the stability of the peptide in these formulations with storage for up to 3 months. Killing of MRSA by P60.4Ac in the two creams was less effective than that by P60.4Ac in the hypromellose gel. In agreement with those findings, P60.4Ac in the hypromellose gel was highly effective in eradicating the two MRSA strains from EMs. We found that even 0.1% (wt/wt) P60.4Ac in the hypromellose gel killed >99% of the viable planktonic bacteria and >85% of the biofilm-associated bacteria on EMs. Hypromellose gels containing 0.1% and 0.5% (wt/wt) P60.4Ac effectively reduced the numbers of viable MRSA cells from BEMs by >90%. No cytotoxic effects of P60.4Ac in the hypromellose gel with up to 2% (wt/wt) P60.4Ac on keratinocytes in EMs and in the hypromellose gel with up to 0.5% (wt/wt) P60.4Ac on epithelial cells in BEMs were observed. High-performance liquid chromatography analysis showed that P60.4Ac was stable in the Softisan cream and the hypromellose gel but not in the Cetomacrogol cream. We conclude that P60.4Ac formulated in hypromellose gel is both stable and highly effective in eradicating MRSA from colonized EMs and BEMs.

Study Information

Provider

pubmed

Year

2016

Date

2016-06-20T00:00:00.000Z

DOI

10.1128/aac.03001-15